InvestorsHub Logo
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Live Updating
profile icon
TerribleTwit Terminated
07/17/14 9:20 AM
profile icon
NathanH Free
03/20/14 10:18 AM
profile icon
Windrider Free
08/30/12 10:10 PM
profile icon
Pick _M_Low Free
08/06/12 3:08 PM
profile icon
Pick _M_Low Free
08/06/12 3:07 PM
profile icon
Pick _M_Low Free
08/06/12 3:06 PM
profile icon
Penny Roger$ Free
07/16/12 8:19 PM
profile icon
Silvr Surfr Free
07/16/12 9:41 AM
profile icon
rarefind Free
07/16/12 8:56 AM
profile icon
Penny Roger$ Free
07/16/12 8:29 AM
profile icon
parabolicplease Free
07/15/12 10:27 PM
profile icon
rarefind Free
07/07/12 4:39 PM
profile icon
rarefind Free
07/06/12 9:16 AM
profile icon
louisa Free
05/31/12 1:11 PM
profile icon
chmcnfunds Free
05/03/12 1:00 PM
profile icon
rarefind Free
04/21/12 10:05 AM
profile icon
gamesetmatch101 Free
04/19/12 2:45 PM
profile icon
chmcnfunds Free
04/19/12 1:47 PM
profile icon
buzz lightyear Free
04/19/12 12:55 PM
profile icon
MoneyBags231 Free
04/19/12 12:46 PM
profile icon
postyle Grandfathered
04/19/12 12:32 PM
profile icon
Flobewan PremiumMember
04/19/12 12:29 PM
profile icon
Flobewan PremiumMember
04/19/12 12:26 PM
profile icon
TerribleTwit Terminated
04/19/12 12:12 PM
profile icon
cicimici83 Free
04/19/12 12:06 PM
profile icon
buzz lightyear Free
04/19/12 12:06 PM
profile icon
buzz lightyear Free
04/19/12 10:49 AM
profile icon
buzz lightyear Free
04/19/12 10:10 AM
profile icon
Flobewan PremiumMember
04/19/12 9:34 AM
profile icon
buzz lightyear Free
04/19/12 9:32 AM
profile icon
Flobewan PremiumMember
04/19/12 9:29 AM
profile icon
TerribleTwit Terminated
04/19/12 9:26 AM
profile icon
TerribleTwit Terminated
04/19/12 9:22 AM
profile icon
TerribleTwit Terminated
04/19/12 9:15 AM
profile icon
TerribleTwit Terminated
04/19/12 9:11 AM
profile icon
surf1944 Free
04/19/12 8:54 AM
profile icon
Flobewan PremiumMember
04/19/12 8:48 AM
profile icon
NotRichYet2 Free
04/19/12 8:42 AM
profile icon
buzz lightyear Free
04/19/12 8:38 AM
profile icon
buzz lightyear Free
04/19/12 8:36 AM
profile icon
Doubleday Free
04/19/12 8:29 AM
profile icon
NotRichYet2 Free
04/19/12 8:13 AM
profile icon
Flobewan PremiumMember
04/19/12 8:12 AM
profile icon
rarefind Free
04/19/12 8:11 AM
profile icon
buzz lightyear Free
04/19/12 8:10 AM
profile icon
chmcnfunds Free
04/19/12 8:07 AM

Human Genome Sciences, Inc (HGSI) RSS Feed

Followers
21
Posters
141
Posts (Today)
0
Posts (Total)
636
Created
06/06/06
Type
Free
Moderators

Human Genome Sciences

            HGSI Still Has Plenty of Room to Grow

July 20, 2009 3:31 PM ET 

 

 
Human Genome Sciences (NASDAQ:HGSI) is a biopharmaceutical company with a pipeline of novel protein and antibody drugs directed toward large markets that have significant unmet medical need.

HGS Home page:


 

 
{C}
Print E-mail
HUMAN GENOME SCIENCES AND NOVOZYMES ANNOUNCE AMENDMENT TO ALBUMIN FUSION LICENSE AGREEMENT

Rockville, Maryland and Nottingham, UK - May 7, 2009 - Human Genome Sciences, Inc. (NASDAQ: HGSI) and Novozymes Biopharma, a part of Novozymes (NASDAQ: NZYM B), today announced that they have amended an existing license agreement to allow both companies to expand application of their proprietary albumin fusion technology.

Under the amended agreement, HGS and Novozymes each has the opportunity to exclusively license and/or sublicense a number of albumin fusion proteins in exchange for royalties and other consideration. No existing HGS or Novozymes products or product rights, including rights licensed to other companies, are affected by these amendments. Financial or other terms of the agreement were not disclosed.

"Genetic fusion of therapeutic proteins to albumin can improve the pharmacology of the proteins, resulting in important benefits to patients," said Barry A. Labinger, Executive Vice President and Chief Commercial Officer, HGS. "For example, with certain therapeutic proteins, albumin fusion may make it possible to dose less frequently and reduce side effects associated with injections. We are pleased to work with Novozymes to broaden the application of albumin fusion technology to new classes of proteins and peptides."

Thomas Videbæk, Executive Vice President, Novozymes, said, "We are delighted to expand this license agreement with HGS. We license both the fusion protein and the yeast expression systems, which have been optimised for producing albumin fusion proteins as the solution that provides an efficacious half-life in patients. Our strength lies in the fact that we focus on solutions and that is why Novozymes is an ideal partner for the pharmaceutical industry. This enables Novozymes to continue to further develop albufuse®, our proprietary albumin fusion technology, and advance our existing and new partnerships."




5/21/2009

 
Human Genome Reports Positive Results For Long-Term Phase 2 Continuation Trial Of Benlysta In SLE Patients - Update
 
Human Genome Sciences Reveals Positive Trial Results Of Lupus Drug, Shares Up - Update
 
Human Genome Sciences Reveals Positive Long-Term Data For BENLYSTA In Patients With Active Systemic Lupus Erythematosus - Quick Facts
 
Human Genome Sciences - Racing To Cure Lupus
 
 
Human Genome Sciences Submits Biologics License Application For ABthrax To FDA -
(RTTNews) - Thursday, (5-21-09) biotechnology company Human Genome Sciences, Inc. (HGSI: News ) announced the submission of a Biologics License Application or BLA with the U.S. Food and Drug Administration or FDA related to human monoclonal antibody drug Abthrax for the treatment of inhalation anthrax.
Anthrax infection is caused by a spore-forming bacterium, Bacillus anthracis, which multiplies in the body and produces lethal toxins.
 
The Rockville, Maryland-based company said the BLA was submitted on the results of the efficacy tests of raxibacumab carried out on rabbits and monkeys. The results exhibited a survival benefit in both rabbits and monkeys, which is needed for launching the efficacy of new drugs used to counter bioterrorism. The submission also includes the results of safety studies of raxibacumab conducted in healthy human volunteers.
 
Raxibacumab is a first-in-class treatment for anthrax, and is being developed under a contract entered into in 2006 with the Biomedical Advanced Research and Development Authority or BARDA.
 
In the first quarter of 2009, under the BARDA contract, HGS achieved its first product sales by initiating the delivery of 20,000 doses of raxibacumab to the U.S. Strategic National Stockpile for emergency use in the treatment of inhalation anthrax.
 
HGS said it generated revenue of $153.8 million in raxibacumab in the first quarter, including $127.8 million in product sales. The company has now completed delivery and expects to recognize at least $8.0 million in additional raxibacumab revenue in the second quarter of 2009. 
 
Commenting on the submission, HGS' senior vice president, development and regulatory affairs, Sally Bolmer said, "Based on the results of our efficacy and safety studies, we believe raxibacumab has the potential to be an important new treatment for inhalation anthrax. In addition, the raxibacumab BLA is the first HGS has submitted, so it represents a significant milestone for our company."

 

 

RELATED STORY LINKS

 

 

Human Genome Shares Rally on Drug Trial At Wall Street Journal, 6/11/2009

 

HGS lupus drug sustained benefits for 4 years 6/11/2009

  CORRECTED - CORRECTED-UPDATE 2-Human Genome says lupus drug... 6/11/2009

UPDATE 3-Human Genome says lupus drug shows positive results 6/11/2009

Human Genome Sciences Announces Completion of Enrollment in... 6/19/2009

Human Genome Sciences to Host July 20 Conference Call to... 7/1/2009

 

 

 

 

Human Genome Sciences to Host July 20 Conference Call to Discuss Top-Line Phase 3 Results for Benlysta(TM) (Formerly Lymphostat-B(R)) in Systemic Lupus Erythematosus

July 1, 2009 7:00 AM ET   All PR Newswire news ROCKVILLE, Maryland, July 1 /PRNewswire-USNewswire/ -- Human Genome Sciences, Inc. HGSI today announced that it expects to have top-line results available on Monday, July 20, from BLISS-52, the first of two pivotal Phase 3 clinical trials of BENLYSTA(TM) (belimumab, formerly LymphoStat-B(R)) in systemic lupus erythematosus (SLE).
 http://www.newscom.com/cgi-bin/prnh/20080416/HGSLOGO
Senior management will host a conference call to discuss the results on Monday, July 20, 2009 at 8:15 AM Eastern. The BLISS-52 data will be submitted for full presentation at an appropriate scientific meeting.
Investors may listen to the call by dialing 888-632-5010 or 913-312-0402, passcode 8364417, five to 10 minutes before the start of the call. A replay of the conference call will be available within a few hours after the call ends. Investors may listen to the replay by dialing 888-203-1112 or 719-457-0820, confirmation code 8364417.
This conference call also will be webcast and may be accessed at www.hgsi.com. Investors interested in listening to the live webcast should log on before the conference call begins in order to download any software required. The archive of the conference call will remain available for several days.
The mission of HGS is to apply great science and great medicine to bring innovative drugs to patients with unmet medical needs.
HGS, Human Genome Sciences, BENLYSTA and LymphoStat-B are trademarks of Human Genome Sciences, Inc.

 


 

Daily Chart



Weekly Chart

 



Corporate Headquarters

Human Genome Sciences, Inc.
14200 Shady Grove Road
Rockville, MD 20850-3338
Phone: (301) 309-8504
Fax: (301) 309-8512

 

 

Volume:
Day Range:
Last Trade Time:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
HGSI Latest News
  • No Recent News Available for this company!
New Post